TRAILR4/TNFRSF10D/DcR2 Antibody (104918R) [Unconjugated]

Human peripheral blood cells were stained with (A) Mouse Anti-Human TRAILR4 Monoclonal Antibody (Catalog # MAB663R) or (B) Mouse IgG1 isotype control antibody (Catalog # MAB002) followed by PE-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B) and Mouse anti-Human CEACAM-8/CD66b APC-conjugated Monoclonal Antibody (Catalog # FAB4246A). View our protocol for Staining Membrane-associated Proteins.

In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633R). The ND50 is typically 0.3-1.8 µg/mL.

Recombinant Human TRAILR4/TNFRSF10D protein was serially diluted 2-fold and captured by Mouse Anti-Human TRAILR4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633R) coated on a Clear Polystyrene Microplate (DY990). Goat Anti-Human TRAILR4/TNFRSF10D Antigen Affinity-purified Polyclonal Antibody (AF633 ) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (DY998) followed by Substrate Solution (DY998) and stopping the enzymatic reaction with Stop Solution (DY994).

• Reactivity: Hu
• Applications: ELISA, Flow, B/N, CyTOF-ready
• Clone: 104918R
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

TRAILR4/TNFRSF10D/DcR2 Antibody (104918R) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D
  Ala56-His211
  Accession # Q9UBN6
• Specificity: Detects human TRAIL R4/TNFRSF10D in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from cell culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA
  • Flow Cytometry 0.25 ug/10^6 cells
  • Neutralization 0.3-1.8 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRAILR4/TNFRSF10D/DcR2 Antibody (104918R) [Unconjugated]

• CD264 antigen
• CD264
• DcR2
• DCR2decoy with truncated death domain
• Decoy receptor 2
• TNF receptor-related receptor for TRAIL
• TNF-related apoptosis-inducing ligand receptor 4
• TNFRSF10D
• TRAIL R4
• TRAILR4
• TRAIL-R4
• TRAILR4TRAIL receptor 4
• TRUNDDTRAIL receptor with a truncated death domain
• tumor necrosis factor receptor superfamily member 10D
• tumor necrosis factor receptor superfamily, member 10d, decoy with truncateddeath domain

Background

Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

1. Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559.
2. Pan, G. et al. (1998) FEBS lett 424:41.
3. Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
4. Degli-Esposti, M.A. et al. (1997) Immunity 7:813.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q9UBN6()